Physostigmine treatment of progressive supranuclear palsy

Cognitive and extrapyramidal effects of cholinomimetic therapy were evaluated in 8 patients with progressive supranuclear palsy. Each was randomized to a 10‐day double‐blind crossover trial of physostigimine and placebo. Physostigmine treatment was associated with marginal and inconsistent changes in long‐term memory, suggesting that cholinergic therapy alone is insufficient to restore cognitive function. Motor scores remained unchanged.

[1]  W. L. Benedict,et al.  Multiple Sclerosis , 2007, Journal - Michigan State Medical Society.

[2]  B. Zalc,et al.  Galactosylceramide: A reliable serum index of demyelination in multiple sclerosis , 1989, Annals of neurology.

[3]  I Litvan,et al.  Slowed information processing in multiple sclerosis. , 1988, Archives of neurology.

[4]  J. Kaye,et al.  Cerebrospinal fluid cholinesterases in aging and in dementia of the alzheimer type , 1988, Annals of neurology.

[5]  R. Mayeux,et al.  Effects of oral physostigmine in Alzheimer's disease , 1987, Annals of neurology.

[6]  E. Giacobini,et al.  The effects of physostigmine on acetylcholinesterase activity of CSF, plasma and brain. A comparison of intravenous and intra ventricular administration in beagle dogs , 1986, Neuropharmacology.

[7]  E. Hirsch,et al.  Dopaminergic and cholinergic lesions in progressive supranuclear palsy , 1985, Annals of neurology.

[8]  K. Davis,et al.  Pharmacological alleviation of cholinergic lesion induced memory deficits in rats. , 1985, Life sciences.

[9]  D L Price,et al.  Basal forebrain neurons in the dementia of Parkinson disease , 1983, Annals of neurology.

[10]  Stéphane Huot,et al.  Simultaneous Determination of 3,4‐Dihydroxyphenylalanine, 5‐Hydroxytryptophan, Dopamine, 4‐Hydroxy‐3‐Methoxyphenylalanine, Norepinephrine, 3,4‐Dihydroxyphenylacetic Acid, Homovanillic Acid, Serotonin, and 5‐Hydroxyindoleacetic Acid in Rat Cerebrospinal Fluid and Brain by High‐Performance Liquid Chro , 1982, Journal of neurochemistry.

[11]  M. Sanders,et al.  Peripheral retinal haemorrhages with papilloedema. , 1980, The British journal of ophthalmology.

[12]  Harvey S. Levin,et al.  Effects of physostigmine and lecithin on memory in Alzheimer disease , 1979, Annals of neurology.

[13]  C. Masters.  PATHOGENESIS OF THE ARNOLD‐CHIARI MALFORMATION: THE SIGNIFICANCE OF HYDROCEPHALUS AND AQUEDUCT STENOSIS , 1977, Journal of neuropathology and experimental neurology.

[14]  A. Borti.  Communicating hydrocephalus causing aqueductal stenosis. , 1976, Neuropadiatrie.

[15]  V. Caviness.  The Chiari Malformations of the Posterior Fossa and Their Relation to Hydrocephalus , 1976, Developmental medicine and child neurology.

[16]  F. Glasauer.  Isotope cisternography and ventriculography in congenital anomalies of the central nervous system. , 1975, Journal of neurosurgery.

[17]  HERMAN BUSCHKE,et al.  Evaluating storage, retention, and retrieval in disordered memory and learning , 1974, Neurology.

[18]  N. Tye,et al.  Effects of physostigmine on the maintenance of discrimination behaviour in rats. , 1974, Neuropharmacology.

[19]  R. Duvoisin.  Cholinergic-anticholinergic antagonism in parkinsonism. , 1967, Archives of neurology.

[20]  J. Olszewski,et al.  Progressive Supranuclear Palsy: A Heterogeneous Degeneration Involving the Brain Stem, Basal Ganglia and Cerebellum With Vertical Gaze and Pseudobulbar Palsy, Nuchal Dystonia and Dementia , 1964 .

[21]  John Brown.  Some Tests of the Decay Theory of Immediate Memory , 1958 .

[22]  R. Garruto,et al.  Epidemiology of tropical spastic paraparesis in colombia and associated HTLV‐I infection , 1988, Annals of neurology.

[23]  for patients with multiple sclerosis , 2022 .